In summary, we used proteomics to create a panel of five serum proteins (SPARC, SERPIND1, C4B, PPIB, and FAM173A) predicting the radiotherapeutic response in NPC patients. This evidence concerns the gene C4B and nasopharyngeal carcinoma.